Table 3. Summary of the HR for miRNA expression in gastric cancer.
| miRNA | Survival analysis | Number of articles | Included references | HR | 95%CI | Figure | P value | Heterogeneity (Higgins I2 statistic) | Total patients |
|---|---|---|---|---|---|---|---|---|---|
| High miR-20a | OS | 3 | 3,5,11 | 1.25 | 0.84-1.87 | 3 | 0.27 | I2=70.7%, P=0.03 | 199 |
| High miR-20b | OS | 3 | 3,12,13 | 2.38 | 1.16-4.87 | 3 | 0.02 | I2=0.0%, P=0.60 | 178 |
| High miR-21 | RFS/CSS | 3 | 6,14,17 | 2.10 | 0.72-6.12 | 2A | 0.17 | I2=65.6%, P=0.06 | 180 |
| High miR-21 | OS | 5 | 3,15,16,18,19 | 1.77 | 1.01-3.08 | 2A | <0.05 | I2=57.8%, P=0.05 | 327 |
| Low miR-27b | OS | 3 | 32-34 | 1.18 | 0.75-1.85 | 3 | 0.47 | I2=36.1%, P=0.21 | 319 |
| Low miR-34a | OS | 5 | 3,38-41 | 1.25 | 0.59-2.65 | 2D | 0.56 | I2=68.4%, P=0.13 | 457 |
| Low miR-34a | OSm | 2 | 38,40 | 1.56 | 0.95-2.55 | 2D | 0.08 | I2=51.0%, P=0.15 | 213 |
| High miR-106b | OS | 2 | 3,45 | 1.84 | 1.15-2.94 | 3 | 0.01 | I2=0.0%, P=0.67 | 157 |
| High miR-107 | OS | 3 | 3,46,47 | 1.52 | 0.42-5.57 | 3 | 0.52 | I2=88.8%, P<0.01 | 248 |
| Low miR-125a | OS | 3 | 49-51 | 2.06 | 1.26-3.37 | 4 | <0.01 | I2=0.0%, P=0.42 | 230 |
| Low miR-137 | OS | 2 | 62,64 | 3.21 | 1.68-6.13 | 4 | <0.01 | I2=6.0%, P=0.35 | 168 |
| Low miR-141 | OS | 2 | 65,67 | 2.47 | 1.34-4.56 | 4 | <0.01 | I2=0.0%, P=0.66 | 125 |
| High miR-143 | OS | 2 | 3,70 | 0.68 | 0.12-3.81 | 4 | 0.66 | I2=48.8%, P=0.16 | 81 |
| Low miR-145 | OS | 3 | 34,56,72 | 1.62 | 1.07-2.46 | 4 | 0.02 | I2=36.9%, P=0.21 | 608 |
| Low miR-146a | OS | 3 | 74-76 | 2.60 | 1.63-4.13 | 5 | <0.01 | I2=14.1%, P=0.31 | 213 |
| High miR-150 | OS | 3 | 12,77,79 | 1.63 | 0.77-3.45 | 5 | 0.20 | I2=47.8%, P=0.15 | 223 |
| High miR-150 | RFS/PFS | 2 | 77,79 | 1.96 | 1.25-3.05 | 5 | <0.01 | I2=0.0%, P=0.79 | 158 |
| Low miR-183 | OS | 3 | 56,83,84 | 1.46 | 0.55-3.83 | 5 | 0.45 | I2=90.2%, P<0.01 | 478 |
| High miR-192 | OS | 3 | 48,79,87 | 1.71 | 0.60-4.85 | 5 | 0.31 | I2=87.0%, P<0.01 | 140 |
| High miR-196a | OS | 4 | 88,90-92 | 2.66 | 1.94-3.63 | 6 | <0.01 | I2=0.0%, P=0.62 | 286 |
| High miR-196b | OS | 4 | 56,91-93 | 1.67 | 1.38-2.02 | 6 | <0.01 | I2=0.0%, P=0.62 | 625 |
| Low miR-200c | OS | 3 | 96,98,99 | 0.65 | 0.16-2.64 | 6 | 0.54 | I2=93.6%, P<0.01 | 276 |
| Low miR-200c | PFS/DFS | 3 | 66,96,98 | 1.20 | 0.60-2.38 | 6 | 0.61 | I2=83.1%, P<0.01 | 241 |
| Low miR-206 | OS | 3 | 104-106 | 2.85 | 1.73-4.70 | 7 | <0.01 | I2=0.0%, P=0.37 | 468 |
| High miR-214 | OS | 4 | 1,34,110,111 | 1.84 | 1.27-2.67 | 7 | <0.01 | I2=23.0%, P=0.27 | 403 |
| Low miR-218 | OS | 3 | 114-116 | 2.61 | 1.74-3.92 | 7 | <0.01 | I2=0.0%, P=0.77 | 220 |
| Low miR-335 | OS | 2 | 41,127 | 0.85 | 0.03-27.50 | 7 | 0.93 | I2=94.9%, P<0.01 | 124 |
| Low miR-451 | OS | 3 | 4,141,143 | 1.73 | 1.19-2.52 | 8 | <0.01 | I2=14.7%, P=0.31 | 332 |
| Low miR-451 | DFS/RFS | 2 | 141,142 | 0.46 | 0.01-31.06 | 8 | 0.72 | I2=95.0%, P<0.01 | 90 |
| Low miR-486-5p | OS | 3 | 56,147,148 | 2.45 | 1.65-3.65 | 8 | <0.01 | I2=40.0%, P=0.19 | 529 |
| Low miR-506 | OS | 3 | 154-156 | 2.07 | 1.33-3.23 | 8 | <0.01 | I2=0.0%, P=0.65 | 288 |
HR: hazard ratios; CI: confidence intervals; OS: overall survival; RFS: recurrence-free survival; CSS: cause-specific survival; PFS: progression-free survival; DFS: disease-free survival; mMultivariate analysis.